Evotec (EVO) Competitors $4.03 +0.02 (+0.50%) Closing price 04:00 PM EasternExtended Trading$4.02 -0.01 (-0.25%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVO vs. TGTX, TLX, VRNA, LNTH, AXSM, GRFS, NUVL, ADMA, PCVX, and KRYSShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), Axsome Therapeutics (AXSM), Grifols (GRFS), Nuvalent (NUVL), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Evotec vs. TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Verona Pharma Lantheus Axsome Therapeutics Grifols Nuvalent ADMA Biologics Vaxcyte Krystal Biotech TG Therapeutics (NASDAQ:TGTX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment. Does the media refer more to TGTX or EVO? In the previous week, TG Therapeutics had 11 more articles in the media than Evotec. MarketBeat recorded 11 mentions for TG Therapeutics and 0 mentions for Evotec. TG Therapeutics' average media sentiment score of 1.55 beat Evotec's score of 1.16 indicating that TG Therapeutics is being referred to more favorably in the media. Company Overall Sentiment TG Therapeutics Very Positive Evotec Positive Is TGTX or EVO more profitable? Evotec has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. Evotec's return on equity of 0.00% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics-5.42% -8.32% -3.40% Evotec N/A N/A N/A Do analysts rate TGTX or EVO? TG Therapeutics currently has a consensus target price of $40.80, suggesting a potential upside of 19.16%. Evotec has a consensus target price of $5.93, suggesting a potential upside of 47.23%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has stronger earnings & valuation, TGTX or EVO? TG Therapeutics has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$386.39M14.07$12.67M$0.24142.67Evotec$788.22M1.82-$90.82MN/AN/A Do insiders and institutionals have more ownership in TGTX or EVO? 58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer TGTX or EVO? TG Therapeutics received 652 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 53.85% of users gave Evotec an outperform vote. CompanyUnderperformOutperformTG TherapeuticsOutperform Votes65976.27% Underperform Votes20523.73% EvotecOutperform Votes753.85% Underperform Votes646.15% Which has more risk and volatility, TGTX or EVO? TG Therapeutics has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. SummaryTG Therapeutics beats Evotec on 11 of the 16 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43B$6.49B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E RatioN/A9.1826.8919.71Price / Sales1.82252.26386.75120.59Price / Cash161.0865.8538.2534.62Price / Book1.186.456.774.50Net Income-$90.82M$144.21M$3.23B$248.22M7 Day Performance2.28%2.46%1.82%0.56%1 Month Performance1.51%4.59%11.12%13.17%1 Year Performance-22.05%-2.68%17.09%7.30% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec1.4949 of 5 stars$4.03+0.5%$5.93+47.2%-21.2%$1.43B$788.22M0.004,200Positive NewsGap DownTGTXTG Therapeutics3.8069 of 5 stars$34.99+4.0%$40.80+16.6%+106.0%$5.56B$386.39M-349.87290Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.25-5.4%$22.00+35.4%N/A$5.49B$783.21M0.00N/AVRNAVerona Pharma2.6573 of 5 stars$67.53+6.6%$81.50+20.7%+492.7%$5.48B$118.54M-35.1730Positive NewsGap DownLNTHLantheus4.4483 of 5 stars$79.52-2.7%$132.67+66.8%-6.9%$5.45B$1.54B13.23700Positive NewsHigh Trading VolumeAXSMAxsome Therapeutics4.7164 of 5 stars$110.16+2.2%$172.14+56.3%+35.4%$5.42B$432.16M-18.39380Positive NewsAnalyst ForecastInsider TradeGRFSGrifols3.1487 of 5 stars$7.73+8.9%N/A+6.8%$5.31B$7.21B6.6126,300News CoveragePositive NewsNUVLNuvalent2.4709 of 5 stars$73.63+5.4%$115.50+56.9%+5.6%$5.27BN/A-21.2240News CoveragePositive NewsADMAADMA Biologics3.1804 of 5 stars$20.45+2.4%$24.25+18.6%+109.6%$4.86B$459.38M73.04530News CoveragePositive NewsPCVXVaxcyte3.0946 of 5 stars$31.59+1.4%$136.50+332.1%-53.9%$4.08BN/A-6.87160Positive NewsKRYSKrystal Biotech4.9053 of 5 stars$139.43+5.5%$218.63+56.8%-24.1%$4.03B$333.45M46.63210Positive News Related Companies and Tools Related Companies TG Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Verona Pharma Alternatives Lantheus Alternatives Axsome Therapeutics Alternatives Grifols Alternatives Nuvalent Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EVO Stock Free EVO Stock Alerts